• Insight Molecular Diagnostics posted Q1 2026 revenue of USD 32,000, down from USD 2.14 million a year earlier, while net loss narrowed to USD 4.29 million, or USD 0.12 per share.
• Gross profit fell to USD 15,000, producing a 46.9% gross margin; operating loss narrowed to USD 4.41 million.
• Operating expenses dropped to USD 4.43 million from USD 8.12 million, including a USD 5.92 million non-cash gain from a change in fair value of contingent consideration.
• Cash, cash equivalents, and restricted cash rose to USD 29.36 million at quarter-end following a USD 26.02 million registered direct offering completed in February.
• FDA review of GraftAssureDx began after a late-March submission, with management still targeting marketing authorization later in 2026; 34 U.S. transplant centers have expressed interest in its GALACTIC registry, with a top-10 Northeast kidney transplant center signing the first trial agreement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insight Molecular Diagnostics Inc. published the original content used to generate this news brief on May 13, 2026, and is solely responsible for the information contained therein.